RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi, Manabu Soda, Yuki Togashi et al. · Nature Medicine · 2012
Cited by 1,313 works. doi:10.1038/nm.2658
Authors
- Kengo Takeuchi
- Manabu Soda
- Yuki Togashi
- Ritsuro Suzuki
- Seiji Sakata
- Satoko Hatano
- Reimi Asaka
- Wakako Hamanaka
- Hironori Ninomiya
- Hirofumi Uehara
- Young Lim Choi
- Yukitoshi Satoh
- Sakae Okumura
- Ken Nakagawa
- Hiroyuki Mano
- Yuichi Ishikawa
References
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
- Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
- PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas
- Activation of a novel human transforming gene, ret, by DNA rearrangement
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
- Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
- Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
- Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non–Small Cell Lung Cancer
- EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers